Daily Brief : June 23: Webb reveals ancient comet, Memento tackles blindness

HEADLINE

Webb telescope traces interstellar comet to a primordial star system 10 billion years old, while a new biotech and expanded Earth-observation contracts reshape infrastructure for science and grid resilience.

THE BIG PICTURE

Today's stories span three infrastructure frontiers: understanding the chemistry of distant planetary systems, building biological treatments for degenerative disease, and integrating commercial satellite data into national observation networks. Each represents a layer of capability, scientific, medical, and informational, that didn't exist twelve months ago. The pattern is deliberate investment in the pipes and platforms that make the next decade of discovery possible.

WHAT HAPPENED

NASA's James Webb Space Telescope has determined that comet 3I/ATLAS, an interstellar visitor, formed between 10 and 12 billion years ago in a primordial planetary system far from our own. Researchers using Webb's Near-Infrared Spectrograph measured the comet's deuterium-to-hydrogen ratio at roughly 30 times higher than any comet in the solar system, offering direct chemical evidence of its ancient, cold origin. Astrophysicist Martin Cordiner of NASA's Goddard Space Flight Center called it 'a unique opportunity to study an ancient object from the distant galaxy, probably pre-dating our Sun and solar system.' The findings, published in *Nature* on June 22, represent humanity's closest chemical sample from another star system without sending a spacecraft across light-years.

Memento Medicines, a Boston-based subsidiary of Sera Medicines, closed a $93 million Series A financing co-led by Forbion, RA Capital Management, and Avego BioScience Capital. The company is developing MMT-205, a bispecific antibody that activates the Tie2 protein while inhibiting VEGF, targeting neovascular age-related macular degeneration and diabetic macular edema, the leading causes of adult blindness in developed economies. First-in-human trials are targeted for 2027. The financing will fund IND-enabling studies and clinical development, with Memento holding exclusive worldwide rights to the asset under licensing agreements with MabTics and Curacle.

NASA's Commercial Space Data and Analytics On-Ramp 2 contract added eight new commercial Earth-observation companies to its roster, including Hydrosat, Muon Space, Orbital Sidekick, and ICEYE US. The $476 million indefinite-delivery, indefinite-quantity contract runs through November 2028 and integrates commercial satellite imagery into federal agencies' Earth-monitoring capabilities, extending the reach of national observation infrastructure without government-owned satellites.

Astrobotic Technology unveiled Griffin-1, a fully integrated lunar lander with 650-kilogram payload capacity, designated for NASA's Moon Base II missions. The company is shipping the lander to NASA's Jet Propulsion Laboratory this week for environmental testing, with a Falcon Heavy launch targeted for the fourth quarter of 2026. Griffin-1 represents the near-term hardware for sustained human presence at the lunar south pole.

WATCHING

FERC is expected to issue a legally durable order on Rule RM26-4-000 by the end of June, clarifying interconnection rules for large electrical loads and data centers seeking grid access. Watch for regulatory clarity on how 20+ megawatt facilities can connect to the grid; this directly impacts AI infrastructure and clean-energy deployment timelines. Also monitor NASA's Wallops Flight Facility for a sounding rocket launch scheduled for June 24, and Botswana's Artemis Accords signing on June 25, widening the coalition of nations committing to lunar governance standards.